Tudorza (Aclidinium bromide) for COPD

Overview
Tudorza is a prescription drug approved by the Food and Drug Administration (FDA) for maintenance treatment of bronchospasm in chronic obstructive pulmonary disease (COPD). Tudorza is not indicated for rescue usage during acute bronchospasms. Tudorza is also known by its drug name, Aclidinium bromide.

Tudorza is a bronchodilator, a drug that dilates the bronchi and bronchioles in the lungs, making it easier to breathe. Tudorza is also a member of the anticholinergic class of medications. Tudorza is believed to work by relaxing smooth muscles in the airways. Tudorza is considered a long-acting bronchodilator.

How do I take it?
Tudorza is inhaled orally twice a day.

Tudorza comes in powdered doses delivered by the specialized Pressair inhaler.

Side effects
The FDA-approved label for Tudorza lists common side effects including include headache, cough, and cold symptoms.

Rare but serious side effects listed for Tudorza include worsening of glaucoma, worsening of urinary retention, hypersensitivity reactions, and paradoxical bronchospasm (bronchospasm caused by taking medication).

For more details about this treatment, visit:

Tudorza.com – Almirall
http://www.tudorza.com/default.aspx